$PHVS News

Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says

RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52

Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40

Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Pharvaris Q2 EPS $(0.81) Misses $(0.74) Estimate

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris: One Molecule Could Reshape Both Sides Of HAE Treatment

Pharvaris (PHVS) Stock May Be Pricey After A 103% Five Year Run

Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology

Here's Why Pharvaris N.V. (PHVS) is a Great Momentum Stock to Buy

Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55

Wall Street Analysts Believe Pharvaris (PHVS) Could Rally 36.16%: Here's is How to Trade

Why This Biotech, Up 12% Since Its Breakout, Yo-Yoed On A Key FDA Development

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027